Report of Foreign Issuer (6-k)
April 24 2017 - 06:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
April 21, 2017
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo Nordisk A/S – Reduction
of the share capital
Bagsværd, Denmark, 21 April 2017
–
At Novo Nordisk’s Annual General Meeting on 23 March 2017, it was decided to reduce the company’s B share capital from
DKK 402,512,800 to DKK 392,512,800 by cancellation of part of the company’s portfolio of own B shares at a nominal value
of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each.
Today, Novo Nordisk has registered the implementation of the reduction
of the share capital with the Danish Business Authority and cancelled nominally DKK 10,000,000 B shares. After the reduction of
the share capital, the company’s share capital is nominally DKK 500,000,000, which is divided into an A share capital of
nominally DKK 107,487,200 and a B share capital of nominally DKK 392,512,800.
The reduction in the share capital will not affect Novo Nordisk’s
share repurchase programme which will continue as previously announced.
Novo
Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has
given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia,
growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,000 people in 77 countries and markets
its products in more than 165 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed
on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
Further information
Media:
|
|
|
Anne Margrethe Hauge
|
+45 3079 3450
|
amhg@novonordisk.com
|
|
|
|
Investors:
|
|
|
Peter Hugreffe Ankersen
|
+45 3075 9085
|
phak@novonordisk.com
|
Hanna Ögren
|
+45 3079 8519
|
haoe@novonordisk.com
|
Anders Mikkelsen
|
+45 3079 4461
|
armk@novonordisk.com
|
Kasper Veje (US)
|
+1 609 235 8567
|
kpvj@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
Internet:
www.novonordisk.com
|
CVR no:
24 25 67 90
|
|
|
Company announcement No 29 / 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: April 21, 2017
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2023 to Mar 2024